Related Experiment Video

Updated: Apr 27, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K

Imatinib: a breakthrough of targeted therapy in cancer

Nida Iqbal1, Naveed Iqbal2

  • 1Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.

Chemotherapy Research and Practice
|June 26, 2014
PubMed

Insights

Imatinib is a targeted cancer therapy drug that inhibits specific tyrosine kinases. It has shown success in treating chronic myeloid leukemia, gastrointestinal stromal tumors, and other cancers, transforming oncology treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Deregulated protein tyrosine kinase activity drives human cancer development.
  • Selective tyrosine kinase inhibitors (TKIs) represent a breakthrough in cancer therapy.
  • Imatinib was an early and successful example of targeted cancer therapy.

Purpose of the Study:

  • To provide a comprehensive review of Imatinib's role in oncology.
  • To highlight Imatinib's mechanism of action and therapeutic applications.
  • To discuss Imatinib's impact on cancer management and other diseases.

Main Methods:

  • Literature review of studies on Imatinib.
  • Analysis of Imatinib's inhibitory targets (BCR-ABL, c-KIT, PDGFRA).
  • Examination of clinical outcomes in various cancers and conditions.

Main Results:

  • Imatinib demonstrates significant efficacy in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
  • The drug benefits other tumors with specific PDGFR and c-KIT abnormalities.
  • Imatinib is effective in steroid-refractory chronic graft-versus-host disease due to its anti-PDGFR activity.

Conclusions:

  • Imatinib is a crucial targeted therapy in oncology with broad applications.
  • Its specific inhibition of key tyrosine kinases offers a paradigm shift in cancer treatment.
  • Imatinib's success underscores the potential of targeted therapies in managing complex diseases.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K